BioCardia (BCDA) Registration Filing summary

Company overview and business model

• Clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases with significant unmet needs.

• Two cell therapy platforms in clinical trials: CardiAMP (autologous) for ischemic heart failure and refractory angina, and CardiALLO (allogeneic) for ischemic heart failure and ARDS.

• Proprietary Helix minimally invasive delivery platform supports both in-house and partnered biotherapeutic development.

Financial performance and metrics

• History of operating losses and ongoing need for substantial additional financing to achieve development and commercialization goals.

• Net tangible book value as of June 30, 2024, was approximately $2.1 million, with 2,123,876 shares outstanding.

• No dividends have been paid and none are expected in the foreseeable future.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for working capital and general corporate purposes, including advancing investigational biotherapeutic candidates and the delivery partnering business.

• Pending use, proceeds will be invested in short- and intermediate-term, interest-bearing instruments.